Veeva Systems (VEEV) stock recently declined 3.07% to $283.73, underperforming a broader market uptick, despite having outperformed its sector and the S&P 500 in prior trading. The company is expected to report Q1 EPS of $1.95 (+11.43% YoY) and revenue of $791.88 million (+13.25% YoY), with full-year estimates also projecting strong growth. VEEV currently holds a Zacks Rank of #3 (Hold) and exhibits a Forward P/E of 37.64, a discount to its industry average, alongside a PEG ratio of 1.6, which is favorable compared to the industry's 3.33.
Veeva Systems (VEEV) experienced a 3.07% decline to $283.73 in its most recent trading session, significantly underperforming the broader market's positive movement, with the S&P 500, Dow, and Nasdaq all gaining around 0.5%. This recent dip contrasts with its prior performance, where VEEV had gained 4.89%, outpacing both the Medical sector and the S&P 500, suggesting a potential short-term correction or profit-taking. The company's fundamental outlook remains robust, with strong growth projected for its upcoming earnings release. Veeva is expected to report Q1 EPS of $1.95, an 11.43% year-over-year increase, and revenue of $791.88 million, up 13.25% year-over-year. Full-year estimates further reinforce this positive trajectory, forecasting EPS growth of 17.88% and revenue growth of 14.26%. Analyst sentiment, as indicated by a 0.17% upward revision in the Zacks Consensus EPS estimate over the last 30 days, points to an improving short-term business trend. Despite a Zacks Rank of #3 (Hold), VEEV's valuation metrics appear attractive; its Forward P/E of 37.64 is at a discount to the industry average of 40.49, and its PEG ratio of 1.6 is significantly lower than the Medical Info Systems industry average of 3.33, an industry favorably ranked in the top 39%.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.40
Ticker Sentiment
